Mednet Logo
SpecialtiesRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

What findings on routine monitoring PFTs prompt you to pursue HRCT in your patients with SARDs?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Mayo Clinic

That’s an excellent question, and the strategy might vary somewhat by the specific SARD, but in general, in any SARD patient undergoing annual PFTs, the presence of any of these should prompt an HRCT to evaluate for the development of ILD. FVC drop ≥ 10% DLCO drop ≥ 15% Moderate decline in FVC (5-9...

Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?

9
5 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

I do screen all newly diagnosed IIM patients with PFTs and chest CT. This has a double purpose: establishing a baseline of lung function and, screening for lung cancer. While the patient might not have lung symptoms on presentation, respiratory involvement can manifest later on the course of the d...

How would you approach a patient referred for esophageal aperistalsis with a longstanding history of Raynaud’s phenomenon, but without other clinical features or serologic findings suggestive of systemic sclerosis?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Michigan

Scleroderma esophagus (distal aperistalsis/absent contractility + hypotensive LES) is a manometric finding, not a diagnosis. There are multiple causes of this finding, including other autoimmune diseases, neuropathic conditions, and metabolic causes.In addition, RP is seen in 3-8% of the population....

In routine clinical practice, how do you operationally define ‘progression despite therapy’ in PPF to justify escalation to combination treatment?

3 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

ILD patients undergo regular monitoring with intervals based on concern for progression. In addition to symptom review, objective testing includes PFTs with spirometry and DLCO, 6-minute walk testing that provides information on distance walked, symptoms experienced, and whether or not the patient d...

Is a history of Zoster ophthalmicus a contraindication to starting upadacitinib?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Legacy Devers Eye Institute

A history of HZO (herpes zoster ophthalmicus) or herpes zoster in any dermatome is a relative contraindication to the use of upadacitinib or any JAK inhibitor. HZO is often a very unpleasant disease with pain, ocular discomfort, and vision loss, so the chance of reactivation should be minimized. The...

What's the best approach for severe calcinosis cutis in a patient with dermatomyositis who is unresponsive to diltiazem and colchicine?

5
7 Answers

Mednet Member
Mednet Member
Rheumatology · Emory University

Calcinosis cutis remains one of the most frustrating, typically recalcitrant manifestations of DM for both patients and physicians.Like Dr.@Dr. First Last, I also find that while there have been multiple case reports or small trials of various regimens published, the disappointing real-world variabi...

How do you explain the use of an AI scribe to patients the first time it is used in their care?

14
5 Answers

Mednet Member
Mednet Member
Psychiatry · University of Maryland School of Medicine

I use an AI scribe in my outpatient clinic, and around 90–95% of my patients agree to it. I obtain consent at the start of each visit and make it clear that it's completely optional—that they can say no at the start or change their mind at any point in the visit, with no impact on their care. I also...

Do the results of FIBRONEER-ILD change your approach to antifibrotic treatment in patients with sarcoidosis related PPF?

3 Answers

Mednet Member
Mednet Member
Pulmonology · Thomas Jefferson University

It changes my thinking somewhat, but I would be careful not to overinterpret the sarcoidosis results. FIBRONEER-ILD supports the broader concept that once different non-IPF ILDs develop a progressive fibrotic phenotype, targeting fibrosis may be beneficial regardless of the original diagnostic label...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

What is the clinical significance of a low titer RNP, negative Sm, but Sm/RNP that is very high titer?

3
1 Answers

Mednet Member
Mednet Member
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Important question as I've seen clinicians incorrectly interpret anti-Sm-RNP as anti-Smith antibody.The different autoantibodies (RNP, Smith, Sm/RNP) react to different antigens as follows: Anti-RNP can react to multiple components (antigens) of the U1 small nuclear RNP particle (snRNP), Anti-Smith ...